[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350054-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350054-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prc2-loss-impairs-small-cell-lung-cancer-tumorigenesis-and-enhances-sensitivity-to-g9aglp-inhibition","PRC2 loss impairs small cell lung cancer tumorigenesis and enhances sensitivity to G9a/GLP inhibition","","Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with limited therapeutic options and poor survival, driving the need for improved targeted strategies. This study dissects Polycomb repressive complex 2 (PRC2) functions in SCLC, showing that conditional deletion of the structural core component Eed prevents tumor formation, whereas EZH2 enzymatic inhibition alters the PRC2 interactome without directly reducing growth. A focused combination screen reveals that prolonged EZH2 inhibition sensitizes neuroendocrine cancer cells to G9a/GLP inhibition, with transcriptomic data linking the combination to an oxidative stress response that can be reversed by antioxidant treatment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prc2-loss-impairs-small-cell-lung-cancer-tumorigenesis-and-enhances-sensitivity-to-g9aglp-inhibition/350054/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prc2-loss-impairs-small-cell-lung-cancer-tumorigenesis-and-enhances-sensitivity-to-g9aglp-inhibition/350054.png","ImageObject",300,407,{"name":42,"@type":43},"\tCallum ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does PRC2 structural loss affect SCLC tumor formation?","Question",{"text":63,"@type":64},"Conditional deletion of Eed, a core structural component of PRC2, prevents tumor formation in an autochthonous SCLC model.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the effect of inhibiting EZH2 enzymatic activity on tumor growth?",{"text":68,"@type":64},"Enzymatic inhibition of EZH2 does not impact tumor growth but significantly alters the PRC2 interactome, indicating changes in potential druggable targets.",{"name":70,"@type":61,"acceptedAnswer":71},"Why does prolonged EZH2 inhibition improve sensitivity to G9a/GLP inhibition?",{"text":72,"@type":64},"The combination triggers an oxidative stress response via modulating cellular oxidase expression, and the effect can be reversed by antioxidant treatment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350054,1790456189,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","communications biology Article  \nA Nature Portfolio journal  \n[https://doi.org/10.1038/s42003-026-09677-w](https://doi.org/10.1038/s42003-026-09677-w)  \nPRC2 loss impairs small cell lung cancer tumorigenesis and enhances sensitivity to G9a/GLP inhibition  \n Check for updates  \nJawahar Kopparam1,2,5, Gayathri Chandrasekaran1,2,5, Danielle Hulsman1,2, Liesa-Marie Pilger 1, Karen Stevers 1, Ji-Ying Song3, Miguel Hernandez-Quiles1,2, Jelmer Dijkstra1,2, Jitendra Badhai1,2, Nick Landman1,2, Michiel Vermeulen 1,2,4 & Maarten van Lohuizen 1,2   \nEffective targeted therapies for small cell lung cancer (SCLC) remain a signiﬁcant challenge. Targeting theepigenome to overcome immune evasion and chemoresistance represents a promising strategyto improve treatment outcomes. In this study, we explored the role of Polycomb repressive complex 2 (PRC2), a key transcriptional repressor, by dissecting its structural and enzymatic functions. Conditional deletion of Eed, a core structural component of PRC2, prevented tumor formation in an autochthonous SCLC model. In contrast, enzymatic inhibition of EZH2had no impact on tumor growth but signiﬁcantly altered the PRC2 interactome, unveiling novel targets for drug development. Since EZH2 inhibitors are already clinically approved for other cancers, we conducted a focused combination drug screen to enhance their therapeutic potential in SCLC. Our ﬁndings revealed that prolonged EZH2 inhibition sensitized neuroendocrine cancer cells to G9a/GLP inhibition. Transcriptomic analysis revealed that the drug combination triggered an oxidative stress response by modulating the expression of cellular oxidases, an effect that could be reversed by antioxidant treatment. These results underscore the critical role of PRC2 ’s structural functions in SCLC and identify promising drug combinations to enhance the efﬁcacy of EZH2 inhibitors.  \nSmall cell lung cancer(SCLC), a highly aggressive neuroendocrine tumor, is often diagnosed at an advanced stage with metastasis, leading to a dismal 5-year survival rate of less than 7%1. The current standard-of-care treatment, including chemotherapy with Immune checkpoint blockade (ICB), offers only modest improvement in overall survival2. SCLC is characterized by substantial tumor heterogeneity, with most primary tumors retaining neuroendocrine (NE) differentiation and exhibiting immunosuppressive features such as repressed antigen presentation3,4. However, only around 15% of the patients have an inﬂamed tumor with functional antigen presentation and T cell inﬁltration, which are crucial for the success of ICB5. These tumors often develop non-neuroendocrine (non-NE) phenotype, a feature commonly associated with chemoresistance in SCLC6,7. These observations highlight the need for strategies that target the plasticity and immunogenicity ofSCLC cells to improve therapeutic responses.  \nRecent studies have identiﬁed epigenetic alterations as central to the plasticity and chemoresistance ofSCLC8,9. One key player in this context is  \nthe Polycomb repressive complex 2 (PRC2), which mediates the trimethylation of histone H3 at lysine 27 (H3K27me3), leading to transcriptional repression5, 10. Genetic screens aimed at identifying regulators ofmajor histocompatibility complex(MHC)class1expression has highlighted PRC2 core components (EED, SUZ12 and EZH2) and other ancillary proteins including MTF2, AEBP2, and BAHD1, as critical modulators of antigen presentation11, 12. Notably, enzymatic inhibition of EZH2 was sufﬁcient to restore antigen presentation and chemosensitivity in SCLC, making it a promising target. As combination of EZH2inhibitor with chemotherapy or other targeted therapies are being evaluated in clinical trials, understanding the precise role of PRC2 components in the pathogenesis of SCLC is essential for optimizing these strategies13.  \nTargeting additional epigenetic modiﬁers such as DOT1L or histone deacetylases can improve the therapeutic potential of EZH2 inhibition in ","cbCaikXKQp9GEEpy","https://ap.wps.com/l/cbCaikXKQp9GEEpy","pdf",1608150,12,"English","# Background and clinical challenge\n## Tumor heterogeneity and immunotherapy limitations\n# PRC2 in SCLC biology\n## PRC2 function and component roles\n# Rationale for combination epigenetic targeting\n## Links between G9a/GLP and PRC2 repression\n# Mechanistic findings and therapeutic implications\n## Oxidative stress response and antioxidant reversal","[{\"question\":\"How does PRC2 structural loss affect SCLC tumor formation?\",\"answer\":\"Conditional deletion of Eed, a core structural component of PRC2, prevents tumor formation in an autochthonous SCLC model.\"},{\"question\":\"What is the effect of inhibiting EZH2 enzymatic activity on tumor growth?\",\"answer\":\"Enzymatic inhibition of EZH2 does not impact tumor growth but significantly alters the PRC2 interactome, indicating changes in potential druggable targets.\"},{\"question\":\"Why does prolonged EZH2 inhibition improve sensitivity to G9a/GLP inhibition?\",\"answer\":\"The combination triggers an oxidative stress response via modulating cellular oxidase expression, and the effect can be reversed by antioxidant treatment.\"}]","PRC2 loss impairs small cell lung cancer tumorigenesis and enhances sensitivity to G9a/GLP inhibition | PDF",1790086931,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe2675181c55f449535574838e028af3.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1cec011ff4e128e3b556cdf5148ea3b.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8e902d4afb7282c45ca598ab48a13bf.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e00b9b04f97e47e8553fdbde9daeb74.webp",980,1301]